{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:26:17Z","timestamp":1777710377828,"version":"3.51.4"},"reference-count":46,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.3960\/jslrt.20019","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T22:05:47Z","timestamp":1596837947000},"page":"66-72","source":"Crossref","is-referenced-by-count":13,"title":["Clinical application of genomic aberrations in adult T-cell leukemia\/lymphoma"],"prefix":"10.3960","volume":"60","author":[{"given":"Keisuke","family":"Kataoka","sequence":"first","affiliation":[{"name":"Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Koya","sequence":"additional","affiliation":[{"name":"Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Tsukasaki K, Hermine O, Bazarbachi A <i>et al.<\/i> Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009; 27: 453-459.","DOI":"10.1200\/JCO.2008.18.2428"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Ishitsuka K, Tamura K. Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. Lancet Oncol. 2014; 15: e517-e526.","DOI":"10.1016\/S1470-2045(14)70202-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Cook LB, Fuji S, Hermine O <i>et al.<\/i> Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. J Clin Oncol. 2019; 37: 677-687.","DOI":"10.1200\/JCO.18.00501"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Matsuoka M, Jeang KT. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer. 2007; 7: 270-280.","DOI":"10.1038\/nrc2111"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Kogure Y, Kataoka K. Genetic alterations in adult T-cell leukemia\/lymphoma. Cancer Sci. 2017; 108: 1719-1725.","DOI":"10.1111\/cas.13303"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kataoka K, Nagata Y, Kitanaka A <i>et al.<\/i> Integrated molecular analysis of adult T cell leukemia\/lymphoma. Nat Genet. 2015; 47: 1304-1315.","DOI":"10.1038\/ng.3415"},{"key":"7","unstructured":"7 Mori N, Fujii M, Ikeda S <i>et al.<\/i> Constitutive activation of NF-kappaB in primary adult T-cell leukemia cells. Blood. 1999; 93: 2360-2368."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ruben S, Poteat H, Tan TH <i>et al.<\/i> Cellular transcription factors and regulation of IL-2 receptor gene expression by HTLV-I tax gene product. Science. 1988; 241: 89-92.","DOI":"10.1126\/science.2838905"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ballard DW, B\u00f6hnlein E, Lowenthal JW <i>et al.<\/i> HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science. 1988; 241: 1652-1655.","DOI":"10.1126\/science.2843985"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Mahgoub M, Yasunaga J, Iwami S <i>et al.<\/i> Sporadic on\/off switching of HTLV-1 Tax expression is crucial to maintain the whole population of virus-induced leukemic cells. Proc Natl Acad Sci USA. 2018; 115: E1269-E1278.","DOI":"10.1073\/pnas.1715724115"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Miura M, Dey S, Ramanayake S <i>et al.<\/i> Kinetics of HTLV-1 reactivation from latency quantified by single-molecule RNA FISH and stochastic modelling. PLoS Pathog. 2019; 15: e1008164.","DOI":"10.1371\/journal.ppat.1008164"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Bangham CRM, Osame M. Cellular immune response to HTLV-1. Oncogene. 2005; 24: 6035-6046.","DOI":"10.1038\/sj.onc.1208970"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Kataoka K, Shiraishi Y, Takeda Y <i>et al.<\/i> Aberrant PD-L1 expression through 3\u2032-UTR disruption in multiple cancers. Nature. 2016; 534: 402-406.","DOI":"10.1038\/nature18294"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16: 275-287.","DOI":"10.1038\/nrc.2016.36"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Nakagawa M, Schmitz R, Xiao W <i>et al.<\/i> Gain-of-function CCR4 mutations in adult T cell leukemia\/lymphoma. J Exp Med. 2014; 211: 2497-2505.","DOI":"10.1084\/jem.20140987"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Li J, Lu E, Yi T, Cyster JG. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. Nature. 2016; 533: 110-114.","DOI":"10.1038\/nature17947"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Shah UA, Chung EY, Giricz O <i>et al.<\/i> North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies. Blood. 2018; 132: 1507-1518.","DOI":"10.1182\/blood-2018-01-824607"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Asanuma S, Yamagishi M, Kawanami K <i>et al.<\/i> Adult T-cell leukemia cells are characterized by abnormalities of Helios expression that promote T cell growth. Cancer Sci. 2013; 104: 1097-1106.","DOI":"10.1111\/cas.12181"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nat Rev Cancer. 2002; 2: 605-615.","DOI":"10.1038\/nrc861"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Sommer K, Guo B, Pomerantz JL <i>et al.<\/i> Phosphorylation of the CARMA1 linker controls NF-kappaB activation. Immunity. 2005; 23: 561-574.","DOI":"10.1016\/j.immuni.2005.09.014"},{"key":"21","unstructured":"21 Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lypm, IARC Press. 2017."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Cairns RA, Iqbal J, Lemonnier F <i>et al.<\/i> IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood. 2012; 119: 1901-1903.","DOI":"10.1182\/blood-2011-11-391748"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Couronn\u00e9 L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. N Engl J Med. 2012; 366: 95-96.","DOI":"10.1056\/NEJMc1111708"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Palomero T, Couronn\u00e9 L, Khiabanian H <i>et al.<\/i> Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet. 2014; 46: 166-170.","DOI":"10.1038\/ng.2873"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Sakata-Yanagimoto M, Enami T, Yoshida K <i>et al.<\/i> Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. Nat Genet. 2014; 46: 171-175.","DOI":"10.1038\/ng.2872"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Cortes JR, Ambesi-Impiombato A, Couronn\u00e9 L, <i>et al<\/i>. RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis. Cancer Cell. 2018; 33 : 259-273 e7.","DOI":"10.1016\/j.ccell.2018.01.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Watatani Y, Sato Y, Miyoshi H <i>et al.<\/i> Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling. Leukemia. 2019; 33: 2867-2883.","DOI":"10.1038\/s41375-019-0473-1"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Heavican TB, Bouska A, Yu J <i>et al.<\/i> Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood. 2019; 133: 1664-1676.","DOI":"10.1182\/blood-2018-09-872549"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Crescenzo R, Abate F, Lasorsa E <i>et al.<\/i> European T-Cell Lymphoma Study Group, T-Cell Project: Prospective Collection of Data in Patients with Peripheral T-Cell Lymphoma and the AIRC 5xMille Consortium \u201cGenetics-Driven Targeted Management of Lymphoid Malignancies\u201d. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015; 27: 516-532.","DOI":"10.1016\/j.ccell.2015.03.006"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Kataoka K, Miyoshi H, Sakata S <i>et al.<\/i> Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019; 33: 1687-1699.","DOI":"10.1038\/s41375-019-0380-5"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Jiang L, Gu ZH, Yan ZX <i>et al.<\/i> Exome sequencing identifies somatic mutations of DDX3X in natural killer\/T-cell lymphoma. Nat Genet. 2015; 47: 1061-1066.","DOI":"10.1038\/ng.3358"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Iqbal J, Weisenburger DD, Greiner TC <i>et al.<\/i> International Peripheral T-Cell Lymphoma Project. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010; 115: 1026-1036.","DOI":"10.1182\/blood-2009-06-227579"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Kataoka K, Iwanaga M, Yasunaga J <i>et al.<\/i> Prognostic relevance of integrated genetic profiling in adult T-cell leukemia\/lymphoma. Blood. 2018; 131: 215-225.","DOI":"10.1182\/blood-2017-01-761874"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Cherian MA, Olson S, Sundaramoorthi H <i>et al.<\/i> An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia. J Biol Chem. 2018; 293: 6844-6858.","DOI":"10.1074\/jbc.RA117.000164"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Bellon M, Lu L, Nicot C. Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia. Blood. 2016; 127: 2439-2450.","DOI":"10.1182\/blood-2015-11-685032"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Jerez A, Clemente MJ, Makishima H <i>et al.<\/i> STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. Blood. 2012; 120: 3048-3057.","DOI":"10.1182\/blood-2012-06-435297"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Koskela HLM, Eldfors S, Ellonen P <i>et al.<\/i> Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012; 366: 1905-1913.","DOI":"10.1056\/NEJMoa1114885"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Katsuya H, Yamanaka T, Ishitsuka K <i>et al.<\/i> Prognostic index for acute- and lymphoma-type adult T-cell leukemia\/lymphoma. J Clin Oncol. 2012; 30: 1635-1640.","DOI":"10.1200\/JCO.2011.38.2101"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Fukushima T, Nomura S, Shimoyama M <i>et al.<\/i> Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014; 166: 739-748.","DOI":"10.1111\/bjh.12962"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Sakamoto Y, Ishida T, Masaki A <i>et al.<\/i> CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment. Blood. 2018; 132: 758-761.","DOI":"10.1182\/blood-2018-02-835991"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Roemer MGM, Advani RH, Ligon AH <i>et al.<\/i> PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016; 34: 2690-2697.","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Roemer MGM, Redd RA, Cader FZ <i>et al.<\/i> Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma. J Clin Oncol. 2018; 36: 942-950.","DOI":"10.1200\/JCO.2017.77.3994"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Wartewig T, Kurgyis Z, Keppler S <i>et al.<\/i> PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis. Nature. 2017; 552: 121-125.","DOI":"10.1038\/nature24649"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44 Ratner L, Waldmann TA, Janakiram M, Brammer JE. Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy. N Engl J Med. 2018; 378: 1947-1948.","DOI":"10.1056\/NEJMc1803181"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45 Font\u00e1n L, Qiao Q, Hatcher JM <i>et al.<\/i> Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. J Clin Invest. 2018; 128: 4397-4412.","DOI":"10.1172\/JCI99436"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46 Ferch U, Kloo B, Gewies A <i>et al.<\/i> Inhibition of MALT1 protease activity is selectively toxic for activated B cell\u2013like diffuse large B cell lymphoma cells. J Exp Med. 2009; 206: 2313-2320.","DOI":"10.1084\/jem.20091167"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/3\/60_20019\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,28]],"date-time":"2021-03-28T00:54:46Z","timestamp":1616892886000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/3\/60_20019\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20019","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}